RecruitingPhase 2NCT03833921
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
Studying Genetic urogenital tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Martha Mims
- Principal Investigator
- Martha Mims, MD, PhDBaylor College of Medicine
- Intervention
- Abiraterone Acetate(drug)
- Enrollment
- 130 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2019 – 2038
Study locations (3)
- Ben Taub General Hospital, Houston, Texas, United States
- Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, Texas, United States
- Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03833921 on ClinicalTrials.govOther trials for Genetic urogenital tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06046131Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.Centre Hospitalier Universitaire de la Guadeloupe
- ACTIVE NOT RECRUITINGNCT03158922The BARCODE 1 Pilot StudyInstitute of Cancer Research, United Kingdom
- ACTIVE NOT RECRUITINGPHASE1NCT00977457Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing SurgeryCity of Hope Medical Center